Antibodies | Dynamics of 1,3-β-D-Glucan in Invasive Candidiasis and Its Diagnostic Significance

This review systematically summarizes the heterogeneity of BDG release among different Candida species, providing critical evidence for the clinical interpretation of negative results in high-risk patients, and suggests that diagnostic strategies should integrate microbiological and molecular testing. It offers direct guidance for the early identification of invasive fungal infections.

 

Literature Overview

The article 'Dynamics of 1,3-β-D-Glucan in Invasive Candidiasis: A Narrative Review of Microbiological Aspects and Diagnostic Implications,' published in the journal 'Antibodies,' systematically explores the microbiological characteristics and diagnostic applications of 1,3-β-D-glucan (BDG) in invasive candidiasis (IC). The article reviews the biological function of BDG as a component of the fungal cell wall, analyzes the differences in detection sensitivity among various Candida species, and evaluates its role and limitations in clinical diagnostic workflows. It further examines the integrative value of complementary technologies such as PCR and blood culture, emphasizing the importance of multimodal diagnostic strategies.

Background Knowledge

Invasive candidiasis (IC) is a major cause of infectious mortality in intensive care units (ICUs), hematology patients, and neonates, with approximately 1.57 million cases globally each year and mortality rates as high as 28–41.6%, imposing a significant healthcare burden, particularly in regions such as Italy. Although blood culture remains the diagnostic gold standard, its sensitivity is low (38–50%) and results are often delayed, leading to treatment delays. Consequently, early serological markers such as BDG have become a clinical focus. However, BDG assay sensitivity is influenced by multiple factors, including the patient's underlying condition (e.g., postoperative status, blood transfusion), nonspecific interferences (e.g., bacterial infections, medications), and crucially—the structural differences in the pathogen's cell wall. Different Candida species exhibit significant variation in BDG exposure, resulting in inconsistent assay performance, a bottleneck that severely limits its application in precise diagnosis. This article systematically reviews the BDG release characteristics of major pathogenic species such as C. albicans, C. glabrata, C. parapsilosis, and C. auris, revealing their impact on diagnostic efficacy and providing a theoretical basis for the rational clinical interpretation of BDG results.

 

 

Research Methods and Experiments

This study employs a narrative review approach, systematically retrieving and synthesizing recent clinical and microbiological research on the use of BDG in invasive candidiasis. The authors focus on analyzing the technical principles, sensitivity, and specificity of different commercial assays (e.g., Fungitell®, Glucatell®, Wako), and by summarizing data from multiple studies, compare BDG detection performance across various Candida species. Additionally, the article delves into the cell biological basis of BDG, integrating existing research on fungal cell wall structure to explain the molecular mechanisms underlying inter-species differences in β-glucan exposure. The authors also evaluate the combined diagnostic value of BDG with technologies such as PCR and blood culture, supporting their arguments with data from multiple prospective and retrospective cohort studies.

Key Conclusions and Perspectives

• BDG is typically released at high levels during C. albicans infection, with detection sensitivity reaching 73–83%, consistent with its high β-1,3-glucan content and partial surface exposure. This supports BDG as a highly sensitive marker in regions where C. albicans is the predominant species.
• Although C. glabrata (now Nakaseomyces glabrata) has high glucan content, its BDG is shielded by a dense outer layer of mannoproteins, resulting in moderate detection sensitivity (~74%). Thus, negative BDG results cannot rule out infection, especially in high-risk patients, and must be interpreted cautiously.
• BDG detection sensitivity is significantly lower in C. parapsilosis and C. auris (63% and 40–60%, respectively), primarily due to unique cell wall structures—limited β-glucan exposure in the former and a dense mannoprotein layer with a complex glucan network in the latter—which restrict antigen release. Therefore, in regions where these species are prevalent, a negative BDG result does not exclude IC.
• Serial monitoring of BDG levels improves positive predictive value and offers prognostic utility: persistently high levels indicate treatment failure or poor outcomes, while decreasing trends correlate with improved survival, supporting its use in assessing treatment response and risk stratification.
• Combining BDG with PCR increases diagnostic sensitivity to 90%, significantly outperforming either method alone, underscoring the necessity of multimodal integration for accurate IC diagnosis.

Research Significance and Prospects

This study provides clinicians and clinical microbiologists with a crucial diagnostic framework: BDG should not be used as a sole exclusion criterion, especially when C. parapsilosis or C. auris infection is suspected. Future efforts should focus on developing novel biomarkers for low-BDG-releasing species or optimizing existing assay thresholds. Additionally, the study supports serial BDG monitoring in high-risk populations to dynamically evaluate treatment efficacy, potentially serving as a key tool for personalized antifungal therapy.

From a translational perspective, this review highlights the importance of pathogen-specific diagnostic strategies. For difficult-to-treat species such as C. auris, molecular methods (e.g., PCR) or culture with susceptibility testing are required, while BDG dynamics can serve as an auxiliary endpoint. Moreover, this work provides a theoretical foundation for developing novel diagnostic algorithms, promoting a shift from 'single-marker' to 'multi-parameter integrated' models, thereby improving the overall management of invasive fungal infections.

 

 

Conclusion

This review systematically elucidates the differences in 1,3-β-D-glucan (BDG) release among Candida species and their impact on diagnostic performance in invasive candidiasis (IC). While BDG performs well as an early serum marker in C. albicans infections, its sensitivity is significantly reduced in C. parapsilosis and the emerging multidrug-resistant pathogen C. auris, primarily due to limited antigen exposure caused by cell wall structure. Therefore, clinical interpretation must integrate patient risk factors, microbial culture, and molecular testing to avoid treatment delays due to false-negative results. Serial monitoring of BDG trends provides prognostic information and supports its use in assessing treatment response. This study emphasizes the necessity of a multimodal diagnostic approach—integrating BDG, PCR, and blood culture—for early and accurate diagnosis. This paradigm is foundational for improving care in critically ill and immunocompromised patients, particularly as the threat of difficult-to-treat fungi like C. auris continues to grow, offering a scientific basis for developing more effective antifungal management strategies.

 

Maddalena Calvo, Marta Caccamo, Dalila Maria Cammarata, and Laura Trovato. Dynamics of 1,3-β-D-Glucan in Invasive Candidiasis: A Narrative Review of Microbiological Aspects and Diagnostic Implications. Antibodies.